The Centre for Health Policy, Health Economics Unit and Cancer Health Services Research Unit collaborate to undertake health technology assessments (HTAs).
The Centre for Health Policy, Health Economics Unit and Cancer Health Services Research Unit collaborate to undertake health technology assessments (HTAs). Activities have supported government decisions about the listing of new medical devices and pharmaceuticals for the Medical Services Advisory Committee (MSAC) and Pharmaceutical Benefits Advisory Committee (PBAC).
The University of Melbourne Health Technology Assessment Group (UoM-HTA) is a large and experienced evaluation team supported by a strong and integrated Leadership Team. The Group Leader is Associate Professor Kim Dalziel who is Head of Health Economics Unit. Professor Maarten IJzerman (Head of Cancer Health Services Research Unit) and Professor Adam Elshaug (Director of Centre for Health Policy) are also part of the Leadership Team.
The UoM-HTA has performed numerous evaluations for PBAC, MSAC, and contracts for Post-market Review and the Prosthesis Reform.
The UoM-HTA is supported by a Scientific Expert Panel comprising of clinical trial, epidemiology, biostatistics and research methodology experts from the Centre for Epidemiology and Biostatistics, vaccine and infectious disease modelling and evaluation, and clinical evaluation, health economics and economic modelling experts from the Methods and Implementation Support for Clinical and Health Research Hub (MISCH) and Centre for Health Policy. The team is also supported by Clinical Expert Panel Members.
The organisation structure of the UoM-HTA is shown in the figure below.